QDEL QuidelOrtho Corporation Common Stock
XNAS
13.77
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
QDEL
$13.77
—
Key stats
$13.77
- 52-Week Range
- $9.92 – $35.58
- YTD
- -52.15%
- IV Rank (30D)
- 92.43
- Straddle Price
- $4.22
- P/C Vol Ratio
- 0.03
- Market Cap
- $0.9B
- Open
- $13.71
- Day Range
- $12.57 – $13.90
- Volume
- 2,179,559
- Prev Close
- $13.73
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.89 |
| Cost of Equity (CAPM) | 9.42% (VRP-adj) |
| WACC | 6.41% |
| Volatility Risk Premium | +69.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +1.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.01 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.2B |
| Return on Equity (TTM) | -59.1% |
| Book / Price | 197.9% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 45.0% |
| FCF Margin (TTM) | -7.9% |
| Debt / Equity | 1.33 |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $12.80 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $12.76 |
| Bollinger Width / SMA20 | 307.6% (drives anchor stability) |
| Net Debt | $2.3B |
| Market Cap | $1B |
Peers used for multiples: ABT, MDT, MMSI, TFX
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$99.88
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 33.1× · 3 peers |
| Peer EV/EBITDA | $83.64 | 28% | median 18.6× · 4 peers |
| Peer P/B | $78.36 | 36% | median 2.9× · 4 peers |
| Peer P/S | $133.89 | 36% | median 3.4× · 4 peers |
| Market Anchor (SMA50) | $12.80 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $13.02 | 0% | 5 strikes · skew +0.70 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES (2835) · industry map
- Exchange
- XNAS
- Market Cap
- $0.9B
- Employees
- 6,500
- List Date
- 1981-08-04
- CIK
- 0001906324
- Next Earnings
- 2026-11-03 (After-Close)
- EPS Forecast
- $0.18 (1 est.)
- Headquarters
- San Diego, CA
- Homepage
- https://www.quidelortho.com
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 31.90% | -23.03% | 0.72% | -8.32% | -3.51% | -5.59% | -1.31% |
| Feb | -35.33% | 3.39% | -1.77% | -34.34% | -5.97% | -17.76% | -15.30% |
| Mar | -23.32% | 8.60% | 4.25% | 5.29% | -10.45% | -27.30% | -7.16% |
| Apr | -19.58% | -11.68% | 0.28% | -13.72% | -18.53% | -25.81% | -14.84% |
| May | 8.80% | -6.10% | -7.43% | 11.37% | 10.01% | 3.01% | 3.28% |
| Jun | 17.19% | 4.79% | -3.26% | -26.11% | -2.80% | 31.99% | 3.63% |
| Jul | 10.01% | 5.08% | 4.94% | 24.22% | -22.73% | -9.15% | 2.06% |
| Aug | -8.00% | -22.23% | -3.20% | 0.60% | 25.78% | -18.52% | -4.26% |
| Sep | 4.14% | -10.35% | -12.66% | 11.25% | 4.25% | -23.35% | -4.45% |
| Oct | -1.16% | 23.28% | -16.00% | -13.93% | -13.63% | 32.66%* | 1.87% |
| Nov | 7.32% | -4.27% | 13.60% | 4.86% | -1.30% | -- | 4.04% |
| Dec | -6.70% | -8.52% | 6.47% | 8.79% | 7.85% | -- | 1.58% |
| Total | -30.04% | -40.59% | -16.51% | -38.57% | -34.07% | -57.14% | -36.15% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $12.76
SMA 50: $12.80
SMA 200: $16.66
Current: $13.77
EMA 12: $13.39
EMA 26: $12.97
MACD: 0.4192 | Signal: 0.1399
BULLISH
ADX (14): 25.98
TREND
+DI: 21.94
−DI: 17.53
Momentum Oscillators
RSI (14): 57.16
NEUTRAL
Stoch %K: 70.08
Stoch %D: 76.18
Williams %R: -30.03
Volume & Volatility
BB Upper: $15.26
BB Lower: $10.26
NEUTRAL
OBV: -38,814,840
Vol SMA 20: 2,311,565
Vol ROC: -20.06%
ATR: $1.03
True Range: $1.33
HV 20: 77.5%
HV 30: 70.4%
HV 60: 91.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers:
- Bearish momentum signals from MACD
- High volatility, indicating increased uncertainty
- Negative news sentiment
Primary Risks:
- Continued market pressure due to high beta
- Potential for a breakout below lower Bollinger Band
Investment Thesis: QuidelOrtho's (QDEL) recent price action is driven by bearish momentum signals and high volatility. While the company has reported positive earnings, its stock has been impacted by negative news sentiment and regulatory concerns. Our analysis suggests that QDEL may experience further downward pressure in the short term.
Recent News Sentiment Impact: The recent headlines have had a mixed impact on the stock's price movement. The positive articles about pregnancy detection kits and the company's CFO retirement have provided some support, while the negative article about the SEC investigation has contributed to the bearish momentum.
Technical Analysis Trend Direction:
- Short-term: BEARISH
- Medium-term: NEUTRAL
- Long-term: BEARISH
Support/Resistance Levels: The stock is currently trading near its lower Bollinger Band, indicating a high level of volatility. The upper band represents strong resistance at $12.90.
Momentum Signals:
- RSI interpretation: OVERSOLD (<30) - potential buy signal
- MACD signal: BEARISH (below signal line)
- Bollinger Bands position: MEAN REVERSION
Volume Analysis: The volume is trending downward, indicating decreasing interest from institutions and traders. The OBV is also negative, suggesting that the decline in price has been driven by selling pressure.
News & Sentiment Analysis Recent Headlines Summary:
- 3 positive news articles about pregnancy detection kits and company events
- 2 negative news articles about regulatory issues and SEC investigation
Sentiment Assessment: The overall sentiment is MIXED, with more bearish articles than bullish ones. However, the positive headlines have provided some support to the stock's price.
Catalyst Identification:
- Earnings release (no date available)
- Regulatory updates (SEC investigation)
Market Narrative: The news has had a mixed impact on the stock's price movement. While some articles have provided support, others have contributed to the bearish momentum.
Risk & Volatility Assessment Beta Interpretation: HIGH RISK (beta >1.5)
Volatility Regime:
- Current volatility is HIGH
- Historical volatility is also HIGH
Options Market Signals: The IV rank is 76.1%, indicating historically high volatility. The put/call ratio is 0.15, suggesting a bullish sentiment.
Downside Protection:
- Support levels: Lower Bollinger Band ($10.03), SMA 20 ($11.46)
- Risk management considerations: Stop-loss levels should be set below $9.50
Market Context & Positioning Sector Performance: QuidelOrtho is trading near the bottom of its sector, indicating a potential buying opportunity.
Institutional Activity: The volume patterns suggest decreasing interest from institutions and traders, which may indicate further selling pressure.
Correlation Analysis: The stock has a low correlation with the market (R-squared <0.5), indicating that it may not be as affected by broader market trends.
Relative Valuation: QuidelOrtho is trading below its 200-day SMA, indicating a potential buying opportunity.
Key Levels & Action Items Critical Price Levels:
- Support: Lower Bollinger Band ($10.03), SMA 20 ($11.46)
- Resistance: Upper Bollinger Band ($12.90)
Breakout/Breakdown Levels:
- Breakout above $13.00 could signal a bullish reversal
- Breakdown below $9.50 could indicate further selling pressure
Time-Sensitive Catalysts: Earnings release (no date available), regulatory updates (SEC investigation)
Risk Management: Stop-loss levels should be set below $9.50, and traders should consider reducing their position size.
Overall Assessment: BEARISH
Generated
News
All QDEL news →
Earnings History
10 of 17 under expected move
Avg Expected Move
13.60%
Avg Actual Move
12.27%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2022-08-04 | After-Close | 10.14% | 5.11% | 0.50x | Within |
| 2022-10-12 | After-Close | 8.16% | 10.53% | 1.29x | Exceeded |
| 2023-01-06 | After-Close | 7.33% | 5.08% | 0.69x | Within |
| 2023-04-13 | After-Close | 10.26% | 5.01% | 0.49x | Within |
| 2023-08-08 | After-Close | 7.70% | 7.27% | 0.94x | Within |
| 2023-10-12 | After-Close | 4.67% | 4.74% | 1.01x | Exceeded |
| 2024-02-13 | After-Close | 8.42% | 32.20% | 3.82x | Exceeded |
| 2024-05-08 | After-Close | 15.58% | 2.20% | 0.14x | Within |
| 2024-07-31 | After-Close | 16.03% | 6.90% | 0.43x | Within |
| 2024-11-07 | After-Close | 17.12% | 12.61% | 0.74x | Within |
| 2025-02-12 | After-Close | 15.34% | 4.28% | 0.28x | Within |
| 2025-05-07 | After-Close | 19.92% | 41.04% | 2.06x | Exceeded |
| 2025-08-05 | After-Close | 18.26% | 1.01% | 0.06x | Within |
| 2025-11-05 | After-Close | 16.26% | 22.32% | 1.37x | Exceeded |
| 2026-02-11 | After-Close | 12.15% | 17.59% | 1.45x | Exceeded |
| 2026-05-05 | After-Close | 20.80% | 6.00% | 0.29x | Within |
| 2026-08-06 | After-Close | 23.13% | 24.72% | 1.07x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
QDEL Options Activity & IV Rank
QDEL IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 126.3%
7-DTE IV: —
Expected Move: $4.22
7-DTE Move: $4.22
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 68
Put Volume: 2
P/C Volume: 0.029
BULLISH
Call OI: 1,099
Put OI: 121
P/C OI: 0.11
Total OI: 1,220
ATM Options Pricing
ATM Call: $1.80
ATM Put: $2.42
Call %: 13.1%
Put %: 17.6%
Chain Summary
Chain Volume: 1,038
Chain OI: 11,886
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 72nd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
72%
vs own history
GEX tilt
+0.61
OI-weighted, today
Vanna tilt
+0.76
δ-sensitivity to IV
Charm tilt
-0.85
δ-decay vs time
Vanna tilt +0.76: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.85: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 6 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 136.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)92.4HighOct 26
Straddle Price (30 DTE)$4.22Oct 26
Beta Analysis
Risk Metrics
Beta: 2.6067
Alpha: -71.64%
Correlation: 0.3642
R-Squared: 13.3%
Stock Volatility: 91.2%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own QDEL
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $12.7M | #1421 of 3716 | +156.0% | 13F | |
| Point72 Hedge fund Steve Cohen | $533K | #1624 of 1945 | -96.0% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $14K | #3860 of 4729 | +165.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
QDEL Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 67,925,000 (as of 2026-03-29)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
8 filers$5.89M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.23M | 37.79% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $1.26M | 21.40% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $872.25K | 14.80% | 2026-06-30 |
| 4 | Walleye Capital LLC | $563.98K | 9.57% | 2026-06-30 |
| 5 | Cubist Systematic Strategies, LLC | $550.72K | 9.35% | 2025-09-30 |
| 6 | Wolverine Trading, LLC Custodian | $320.57K | 5.44% | 2025-09-30 |
| 7 | Gem Investment Advisors, LLC | $92.83K | 1.58% | 2026-06-30 |
| 8 | Raiffeisen Bank International AG | $4.54K | 0.08% | 2026-06-30 |
6 filers$8.59M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $3.74M | 43.56% | 2026-06-30 |
| 2 | D. E. Shaw & Co., Inc. Custodian | $2.25M | 26.19% | 2026-06-30 |
| 3 | Walleye Capital LLC | $1.02M | 11.86% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $725.12K | 8.44% | 2026-06-30 |
| 5 | Cubist Systematic Strategies, LLC | $477.09K | 5.55% | 2025-09-30 |
| 6 | Wolverine Trading, LLC Custodian | $378.33K | 4.40% | 2025-09-30 |
QDEL Insider Trading (Form 4)
Latest: 2026-10-19Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Jonathan Philip Siegrist | EVP of R&D & CTO | Mixed | +11,962 | $13.91 | -$93.1K | EDGAR |
| 2026-09-17 | Ronald Lee Bowman | Chief Human Resources Officer | Mixed | +1,645 | $10.63 | -$9.8K | EDGAR |
| 2026-08-18 | Bryan Michael Hanson | EVP Global Port. Mgmt & Mkting | Mixed | +284 | $14.30 | -$2.3K | EDGAR |
| 2026-07-16 | Micah W Young | Chief Financial Officer | Grant (A) | +356,555 RSU | — | EDGAR | |
| 2026-07-02 | Bryan Michael Hanson | EVP Global Port. Mgmt & Mkting | Mixed | +3,701 | $18.18 | -$38.1K | EDGAR |
| 2026-06-29 | Evelyn S Dilsaver | Director | Grant (A) | +15,532 RSU | — | EDGAR | |
| 2026-06-29 | R Scott Huennekens | Director | Grant (A) | +15,532 RSU | — | EDGAR | |
| 2026-06-29 | Edward L. Michael | Director | Grant (A) | +20,098 RSU | — | EDGAR | |
| 2026-06-29 | Kenneth F Buechler | Director | Grant (A) | +31,397 RSU | — | EDGAR | |
| 2026-06-29 | John R Chiminski | Director | Grant (A) | +22,188 RSU | — | EDGAR | |
| 2026-06-29 | Kenneth J Widder | Director | Grant (A) | +24,185 RSU | — | EDGAR | |
| 2026-06-29 | Ann D Rhoads | Director | Grant (A) | +19,599 RSU | — | EDGAR | |
| 2026-06-29 | Mary Lake Ph D Polan | Director | Grant (A) | +22,743 RSU | — | EDGAR | |
| 2026-06-29 | Joseph D Wilkins Jr. | Director | Grant (A) | +15,532 RSU | — | EDGAR | |
| 2026-06-09 | Edward L. Michael | Director | Award (A) | +1,252 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
QDEL Insider Holdings
17 insiders · @ $13.77
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Kenneth F Buechler | Director | 110,509 | $1.52M | -$5.36M | 52 | 2026-06-29 |
| 2 | Brian J. Blaser | President and CEO | 85,974 | $1.18M | $1.00M | 9 | 2026-05-19 |
| 3 | Joseph M. Busky | Chief Financial Officer | 51,702 | $711.9K | $383.5K | 19 | 2026-02-19 |
| 4 | Matthew Strobeck | Director | 51,234 | $705.5K | $1.52M | 21 | 2026-06-02 |
| 5 | Kenneth J Widder | Director | 45,073 | $620.7K | -$112.0K | 32 | 2026-06-29 |
| 6 | Michelle A Hodges | Chief Legal Officer | 42,753 | $588.7K | $0 | 41 | 2026-02-10 |
| 7 | Mary Lake Ph D Polan | Director | 37,795 | $520.4K | -$12.08M | 69 | 2026-06-29 |
| 8 | Edward L. Michael | Director | 29,144 | $401.3K | $1.01M | 24 | 2026-06-29 |
| 9 | Jonathan Philip Siegrist | EVP of R&D & CTO | 25,381 | $349.5K | $0 | 5 | 2026-10-19 |
| 10 | Ann D Rhoads | Director | 23,257 | $320.2K | $21.2K | 20 | 2026-06-29 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
QDEL Board & Officers
As of SEC filings through Oct 19, 2026Directors 9
- Evelyn S Dilsaver · since May 27, 2022
- Edward L. Michael · listed since May 2023
- Kenneth F Buechler · listed since May 2023
- Kenneth J Widder · listed since May 2023
- Mary Lake Ph D Polan · listed since May 2023
- Ann D Rhoads · listed since May 2023
- Joseph D Wilkins Jr. · listed since May 2023
- John R Chiminski · since Dec 6, 2024
- R Scott Huennekens · since Dec 6, 2024
Officers 7
- Brian J. Blaser · President and CEO · since May 6, 2024
- Micah W Young · Chief Financial Officer · since Jul 6, 2026
- Ronald Lee Bowman · Chief Human Resources Officer · since Aug 26, 2024
- Philip D. McLellan · Chief Operations Officer · since Nov 15, 2024
- Nathaniel Sisitsky · Chief Legal Officer · since Mar 23, 2026
- Jonathan Philip Siegrist · EVP of R&D & CTO · since Oct 7, 2024
- Bryan Michael Hanson · EVP Global Port. Mgmt & Mkting · since Feb 4, 2026
Changes in the last 10 years (91)
| Jul 6, 2026 | Micah W Young became Chief Financial Officer |
| Jun 22, 2026 | The company announced the departure of Joseph M. Busky from the board in an SEC filing |
| Mar 23, 2026 | Nathaniel Sisitsky became Chief Legal Officer |
| Mar 18, 2026 | The company announced the departure of Michelle A Hodges as Chief Legal Officer in an SEC filing |
| Feb 9, 2026 | The company announced the departure of Joseph M. Busky as Chief Financial Officer in an SEC filing |
| Feb 4, 2026 | Bryan Michael Hanson became EVP Global Port. Mgmt & Mkting |
| Jan 30, 2026 | The company announced the departure of Matthew Strobeck from the board in an SEC filing |
| Dec 6, 2024 | R Scott Huennekens became a director |
| Dec 6, 2024 | John R Chiminski became a director |
| Nov 21, 2024 | TC Group VI Cayman, L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 21, 2024 | TC Group VI Cayman, L.L.C. reported in an SEC filing no longer being a 10% owner |
| Nov 21, 2024 | TC Group Cayman Investment Holdings, L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 21, 2024 | TC Group Cayman Investment Holdings Sub L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 21, 2024 | Carlyle Partners VI Cayman Holdings, L.P. reported in an SEC filing no longer being a 10% owner |
| Nov 21, 2024 | Carlyle Holdings II L.L.C. reported in an SEC filing no longer being a 10% owner |
| Nov 21, 2024 | Carlyle Holdings II GP L.L.C. reported in an SEC filing no longer being a 10% owner |
| Nov 21, 2024 | Carlyle Group Inc. reported in an SEC filing no longer being a 10% owner |
| Nov 21, 2024 | CG Subsidiary Holdings L.L.C. reported in an SEC filing no longer being a 10% owner |
| Nov 20, 2024 | The company announced the departure of James Prutow from the board in an SEC filing |
| Nov 15, 2024 | Philip D. McLellan became Chief Operations Officer |
| Nov 12, 2024 | Michelle A Hodges listed as Chief Legal Officer (previously SVP, General Counsel) in SEC filings |
| Oct 7, 2024 | Jonathan Philip Siegrist became EVP of R&D & CTO |
| Sep 17, 2024 | Robert Joseph Bujarski listed as EVP & COO (previously Interim President, EVP & COO) in SEC filings |
| Aug 26, 2024 | Ronald Lee Bowman became Chief Human Resources Officer |
| May 6, 2024 | Brian J. Blaser became President and CEO |
| Feb 29, 2024 | Robert Joseph Bujarski listed as Interim President, EVP & COO (previously EVP & COO) in SEC filings |
| Feb 29, 2024 | Michael S. Iskra listed as Interim CEO, EVP & CCO (previously EVP & Cco) in SEC filings |
| Feb 17, 2024 | The company announced the departure of Douglas C Bryant from the board in an SEC filing |
| Nov 28, 2023 | James Prutow became a director |
| Nov 27, 2023 | The company announced the departure of Stephen H. Wise from the board in an SEC filing |
| Aug 14, 2023 | The company announced the departure of Christopher M Smith from the board in an SEC filing |
| May 25, 2023 | Joseph D Wilkins Jr. first listed as a director in an SEC filing |
| May 25, 2023 | Ann D Rhoads first listed as a director in an SEC filing |
| May 16, 2023 | Patrick Klein became Chief Administrative Officer |
| May 16, 2023 | Matthew Strobeck first listed as a director in an SEC filing |
| May 16, 2023 | Mary Lake Ph D Polan first listed as a director in an SEC filing |
| May 16, 2023 | Louise Brandy became SVP, Chief Information Officer |
| May 16, 2023 | Kenneth J Widder first listed as a director in an SEC filing |
| May 16, 2023 | Kenneth F Buechler first listed as a director in an SEC filing |
| May 16, 2023 | Edward L. Michael first listed as a director in an SEC filing |
| Mar 30, 2023 | Werner Kroll first listed as SVP, Research & Development in an SEC filing |
| Mar 30, 2023 | Robert Joseph Bujarski first listed as EVP & COO in an SEC filing |
| Mar 30, 2023 | Michelle A Hodges first listed as SVP, General Counsel in an SEC filing |
| Mar 30, 2023 | Michael S. Iskra listed as EVP & Cco (previously Chief Commercial Officer) in SEC filings |
| Feb 27, 2023 | Douglas C Bryant first listed as a director in an SEC filing |
| Feb 27, 2023 | Douglas C Bryant first listed as President & CEO in an SEC filing |
| Jun 1, 2022 | William J. Ferenczy reported in an SEC filing no longer being SVP, Cardio/Metabolic Unit |
| Jun 1, 2022 | Werner Kroll reported in an SEC filing no longer being SVP, R&D |
| Jun 1, 2022 | Tamara A. Ranalli reported in an SEC filing no longer being SVP, Molecular Bus. Unit |
| Jun 1, 2022 | Robert Joseph Bujarski reported in an SEC filing no longer being Chief Operating Officer |
| Jun 1, 2022 | Michelle A Hodges reported in an SEC filing no longer being SVP, General Counsel |
| Jun 1, 2022 | Matthew Strobeck reported in an SEC filing no longer being a director |
| Jun 1, 2022 | Mary Lake Ph D Polan reported in an SEC filing no longer being a director |
| Jun 1, 2022 | Kenneth J Widder reported in an SEC filing no longer being a director |
| Jun 1, 2022 | Kenneth F Buechler reported in an SEC filing no longer being a director |
| Jun 1, 2022 | Joseph M. Busky first on file as a director |
| Jun 1, 2022 | Joseph D Wilkins Jr. reported in an SEC filing no longer being a director |
| Jun 1, 2022 | Edward L. Michael reported in an SEC filing no longer being a director |
| Jun 1, 2022 | Douglas C Bryant reported in an SEC filing no longer being a director |
| Jun 1, 2022 | Douglas C Bryant reported in an SEC filing no longer being President & CEO |
| Jun 1, 2022 | Ann D Rhoads reported in an SEC filing no longer being a director |
| May 27, 2022 | TC Group VI Cayman, L.P. became a 10% owner |
| May 27, 2022 | TC Group VI Cayman, L.L.C. became a 10% owner |
| May 27, 2022 | TC Group Cayman Investment Holdings, L.P. became a 10% owner |
| May 27, 2022 | TC Group Cayman Investment Holdings Sub L.P. became a 10% owner |
| May 27, 2022 | Stephen H. Wise became a director |
| May 27, 2022 | Robert R. Schmidt became a director |
| May 27, 2022 | Michael S. Iskra became Chief Commercial Officer |
| May 27, 2022 | Joseph M. Busky became Chief Financial Officer |
| May 27, 2022 | Evelyn S Dilsaver became a director |
| May 27, 2022 | Christopher M Smith became a director |
| May 27, 2022 | Carlyle Partners VI Cayman Holdings, L.P. became a 10% owner |
| May 27, 2022 | Carlyle Holdings II L.L.C. became a 10% owner |
| May 27, 2022 | Carlyle Holdings II GP L.L.C. became a 10% owner |
| May 27, 2022 | Carlyle Group Inc. became a 10% owner |
| May 27, 2022 | CG Subsidiary Holdings L.L.C. became a 10% owner |
| Feb 26, 2021 | Joseph D Wilkins Jr. became a director (predecessor company) |
| Feb 2, 2021 | Karen Gibson listed as SVP, Digital Health (previously SVP, IS & Bus. Transformation) in SEC filings (predecessor company) |
| Dec 1, 2020 | Michelle A Hodges became SVP, General Counsel (predecessor company) |
| Sep 16, 2020 | Robert Joseph Bujarski listed as Chief Operating Officer (previously SVP, NA Comm Ops & Gen Counsel) in SEC filings (predecessor company) |
| Aug 24, 2020 | Tamara A. Ranalli became SVP, Molecular Bus. Unit (predecessor company) |
| Aug 24, 2020 | Ann D Rhoads became a director (predecessor company) |
| May 18, 2020 | William J. Ferenczy became SVP, Cardio/Metabolic Unit (predecessor company) |
| Nov 20, 2019 | Robert Joseph Bujarski listed as SVP, NA Comm Ops & Gen Counsel (previously SVP, Bus Dev & Gen Counsel) in SEC filings (predecessor company) |
| Oct 15, 2019 | Edward Keith Russell listed as SVP, Business Development (previously S.V.P., N.A. Commercial Ops) in SEC filings (predecessor company) |
| Jun 20, 2019 | Kathy Ordonez became a director (predecessor company) |
| Feb 11, 2019 | Karen Gibson became SVP, IS & Bus. Transformation (predecessor company) |
| Dec 14, 2018 | Edward L. Michael became a director (predecessor company) |
| Apr 4, 2018 | Matthew Strobeck became a director (predecessor company) |
| Jan 23, 2018 | Edward Keith Russell listed as S.V.P., N.A. Commercial Ops (previously SVP-Global Commercial Ops) in SEC filings (predecessor company) |
| Oct 16, 2017 | Ratan S Borkar became SVP, Intl Comm Operations (predecessor company) |
Not reported recently (17)
- Robert Joseph Bujarski · Last reported as EVP & COO in an SEC filing dated Oct 17, 2024
- Werner Kroll · Last reported as SVP, Research & Development in an SEC filing dated Jul 30, 2024
- Michael S. Iskra · Last reported as Interim CEO, EVP & CCO in an SEC filing dated Jun 4, 2024
- Robert R. Schmidt · Last reported as a director in an SEC filing dated May 14, 2024
- Louise Brandy · Last reported as SVP, Chief Information Officer in an SEC filing dated Apr 30, 2024
- Patrick Klein · Last reported as Chief Administrative Officer in an SEC filing dated Feb 16, 2024
- Douglas C Bryant · Last reported as President & CEO in an SEC filing dated Feb 12, 2024
- Randall J Steward · Last reported as Chief Financial Officer in an SEC filing dated Feb 7, 2022
- Charles P Slacik · Last reported as a director in an SEC filing dated Jan 27, 2022
- Edward Keith Russell · Last reported as SVP, Business Development in an SEC filing dated Jan 19, 2022
- Kathy Ordonez · Last reported as a director in an SEC filing dated May 20, 2021
- Karen Gibson · Last reported as SVP, Digital Health in an SEC filing dated Feb 19, 2021
- Michael Donald Abney Jr. · Last reported as SVP - Distribution in an SEC filing dated Feb 2, 2021
- Ratan S Borkar · Last reported as SVP, Intl Comm Operations in an SEC filing dated Jan 13, 2021
- Jack W Schuler · Last reported as a director in an SEC filing dated May 18, 2020
- Thomas D Brown · Last reported as a director in an SEC filing dated Feb 26, 2019
- John Tamerius · Last reported as SVP, Strat & Ext Affairs in an SEC filing dated Feb 8, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
QDEL Proposed Insider Sales (Form 144)
Latest: 2025-11-25
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2025-11-25 | KENNETH WIDDER | Director | 4,026 | $112.0K | 2025-11-25 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-01-06 | The Bujarski 2007 Trust U/A Dtd 09/18/2007 | Former COO | 100,200 | $4.76M | 2025-01-06 | UBS Financial Services Inc | — | EDGAR |
| 2024-12-09 | Robert Bujarski | Former COO | 20,000 | $808.0K | 2024-12-09 | UBS Financial Services Inc | — | EDGAR |
| 2024-08-05 | Carlyle Partners VI Cayman Holdings, L.P. | 10% Stockholder | 246,775 | $10.37M | 2024-08-06 | BofA Securities Inc | 10b5-1 | EDGAR |
| 2024-06-12 | Carlyle Partners VI Cayman Holdings, L.P. | 10% Stockholder | 3,953,225 | $158.17M | 2024-06-12 | BofA Securities Inc | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
77 ETFs hold QDEL
25 shown · $260.20M total exposure · 0.06% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.05% | $56.1M | $104.0B | 2026-10-23 |
| 2 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.15% | $48.7M | $32.2B | 2026-10-23 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $24.1M | $74.6B | 2026-10-23 |
| 4 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $22.9M | — | 2026-09-30 |
| 5 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.01% | $16.3M | — | 2026-09-30 |
| 6 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.02% | $10.6M | — | 2026-09-30 |
| 7 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.06% | $8.8M | $13.9B | 2026-10-23 |
| 8 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.05% | $8.6M | $15.8B | 2026-10-23 |
| 9 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $8.2M | — | 2026-09-30 |
| 10 | IJS iShares S&P Small-Cap 600 Value ETF | iShares (BlackRock) | 0.10% | $7.8M | $7.7B | 2026-10-23 |
| 11 | SLYV State Street® SPDR® S&P 600™ Small Cap Value ETF | SPDR (State Street) | 0.10% | $4.9M | $4.8B | 2026-10-23 |
| 12 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.02% | $4.7M | — | 2026-10-23 |
| 13 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.20% | $4.7M | — | 2026-06-30 |
| 14 | IHI iShares U.S. Medical Devices ETF | iShares (BlackRock) | 0.12% | $4.4M | $3.6B | 2026-10-23 |
| 15 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $4.2M | — | 2026-09-30 |
| 16 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $4.2M | — | 2026-05-31 |
| 17 | RWJ Invesco S&P SmallCap 600 Revenue ETF | Invesco | 0.18% | $3.7M | — | 2026-10-24 |
| 18 | FFSM Fidelity Fundamental Small-Mid Cap ETF | Nport | 0.19% | $2.8M | — | 2026-07-31 |
| 19 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.04% | $2.6M | — | 2026-09-30 |
| 20 | XHE State Street® SPDR® S&P® Health Care Equipment ETF | SPDR (State Street) | 1.68% | $2.5M | $151.1M | 2026-10-23 |
| 21 | FNDX Schwab Fundamental U.S. Large Company ETF | Nport | 0.01% | $2.2M | — | 2026-05-31 |
| 22 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $2.2M | — | 2026-09-30 |
| 23 | MGMT BALLAST SMALL/MID CAP ETF | Nport | 0.99% | $1.8M | — | 2026-06-30 |
| 24 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.05% | $1.7M | $3.2B | 2026-10-23 |
| 25 | VIOV Vanguard S&P Small-Cap 600 Value ETF | Vanguard | 0.08% | $1.5M | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-17.80
TTM Revenue
$2.66B
TTM Net Income
$-1.21B
TTM Op. Cash Flow
$6.60M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-29 | $619.80M | $-91.80M | $-1.35 | $-33.00M |
| Q4 '25 | 2025-12-28 | $723.60M | $-130.70M | $-1.90 | $131.90M |
| Q3 '25 | 2025-09-28 | $699.90M | $-733.00M | $-10.78 | $-45.50M |
| Q2 '25 | 2025-06-29 | $613.90M | $-255.40M | $-3.77 | $-46.80M |
| Q1 '25 | 2025-03-30 | $692.80M | $-12.70M | $-0.19 | $65.60M |
| Q4 '24 | 2024-12-29 | $707.80M | $-178.40M | $-2.62 | $63.70M |
| Q3 '24 | 2024-09-29 | $727.10M | $-19.90M | $-0.30 | $117.90M |
| Q2 '24 | 2024-06-30 | $637.00M | $-147.70M | $-2.20 | $-97.90M |
| Q1 '24 | 2024-03-31 | $711.00M | $-1.71B | $-25.50 | $-700.00K |
| Q4 '23 | 2023-12-31 | $742.60M | $7.00M | $0.11 | $80.40M |
| Q3 '23 | 2023-10-01 | $744.00M | $-12.70M | $-0.19 | $41.50M |
| Q2 '23 | 2023-07-02 | $665.10M | $-53.20M | $-0.80 | $-30.60M |
Q1 2026 • period ending 2026-03-29 • filed 2026-05-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.51
P/S
0.35
EV/EBITDA
7.63
EV/Sales
1.22
ROE
-65.4%
ROA
-21.5%
Div Yield
0.00%
FCF Yield
0.71%
Debt/Equity
1.33
Current Ratio
—
Market Cap
$935.33M
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
14.95M
SI % of Float
22.08%
Days to Cover
10.98
Short Vol Ratio
27.0%
Free Float
67.71M
Float %
98.7%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14